RxDoctor Payments Data

Shirley Zeng, PA

Physician Assistant · Brooklyn, NYNPI 1114376290

Payments from drug & device makers

$1,845in general payments, 2019–2025

Across 73 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$587
  • Alnylam Pharmaceuticals Inc.$353
  • Astellas Pharma US Inc$146
  • Civco Medical Instruments$77
  • Novo Nordisk$76
  • Merck$72
  • plus $533 from 14 others

What the payments were for

  • Food & beverage$1,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,845 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$57,139
Medicare patients
247
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron211$128,833
MyrbetriqMirabegron176$116,627
Tamsulosin Hcl450$5,013
Solifenacin Succinate76$5,004
Alfuzosin Hcl ErAlfuzosin Hcl276$4,707
Estradiol81$4,372
Trospium Chloride125$3,822
Potassium Citrate ErPotassium Citrate24$3,386
Silodosin39$2,923
Finasteride245$2,859
Trospium Chloride ErTrospium Chloride14$2,683
Methenamine Hippurate32$2,106
Oxybutynin Chloride ErOxybutynin Chloride72$1,115
Cefpodoxime Proxetil28$926
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip35$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$587$128,833211 claims
Astellas Pharma US IncMyrbetriq$146$116,627176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →